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Pavia, Naples, Rome, Monza, Padua, Turin, and Ragusa, Italy, and Cambridge, United KingdomBackground: Hemophagocytic lymphohistiocytosis (HLH) is a
rare life-threatening disease affecting mostly children but also
adults and characterized by hyperinflammatory features.
A subset of patients, referred to as having familial
hemophagocytic lymphohistiocytosis (FHL), have various
underlying genetic abnormalities, the frequencies of which have
not been systematically determined previously.
Objective: This work aims to further our understanding of the
pathogenic bases of this rare condition based on an analysis of
our 25 years of experience.
Methods: From our registry, we have analyzed a total of 500
unselected patients with HLH.
Results: Biallelic pathogenic mutations defining FHL were
found in 171 (34%) patients; the proportion of FHL was much
higher (64%) in patients given a diagnosis during the first year
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188UNC13D (FHL3) accounted for 70% of cases of FHL. Overall, a
genetic diagnosis was possible in more than 90% of our patients
with FHL. Perforin expression and the extent of degranulation
have been more useful for diagnosing FHL than
hemophagocytosis and the cytotoxicity assay. Of 281 (56%)
patients classified as having ‘‘sporadic’’ HLH, 43 had
monoallelic mutations in one of the FHL-defining genes. Given
this gene dosage effect, FHL is not strictly recessive.
Conclusion: We suggest that the clinical syndrome HLH
generally results from the combined effects of an exogenous
trigger and genetic predisposition. Within this combination,
different weights of exogenous and genetic factors account for the
wide disease spectrum that ranges fromHLH secondary to severe
infection to FHL. (J Allergy Clin Immunol 2016;137:188-96.)
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In an article published in The Lancet in 1939, Bodley-Scott and
Robb-Smith reported 4 patients originally given a diagnosis of
‘‘atypical Hodgkin disease.’’1 The patients had unrelenting fever,
lymphadenopathy, and rather massive hepatosplenomegaly. The
authors stated that ‘‘where the cause of a morbid process is un-
known its diagnosis commonly rests on the changes in the pa-
tient’s tissues; thus ultimately the diagnosis can only be made
with certainty by the microscope.’’ In their cases the ultimate
microscopic analysis wasmade postmortem because all 4 patients
died. The authors were struck by the massive abundance of histio-
cytes in the spleen, liver, and other organs and by the prominent
feature of erythrophagocytosis: they found 6 similar patients in
the literature and coined the term ‘‘histiocytic medullary reticulo-
sis.’’1 Only the initial letter of histiocytes has survived in current
acronyms, but we have little doubt that that article was the first
clinicopathologic description of what we call today hemophago-
cytic lymphohistiocytosis (HLH). Some years later, Farquhar
andClaireaux2 described the first example of familial hemophago-
cytic lymphohistiocytosis (FHL), an entity for which other names
in the literature have been ‘‘genetic’’ or ‘‘primary’’ HLH.3,4 FHL is
now defined on the basis of biallelic mutation in one of a set of
functionally related genes or on familial recurrence. For clinical
purposes, disease reactivation after initial remission has also
been regarded as supporting the diagnosis of FHL.
From the functional point of view, in patients with FHL, defects
of killing by T cells and natural killer (NK) cells have been
prominent, and these can be identified by using appropriate tests.
Over the last 15 years, it has been discovered that these defects are
the consequence of mutations in one of a few genes (PRF1,
UNC13D, STX11, and STXBP2) that are involved in exocytosis
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target cells.5-9 FHL can also be caused bymutations in other genes
(SH2D1A, XIAP, RAB27A, LYST, and AP3B1) associated with the
X-linked lymphoproliferative syndrome (XLP) disorders XLP1
and XLP2,10 Griscelli syndrome type 2,11 Chediak-Higashi syn-
drome,12,13 and Hermansky-Pudlak syndrome.14 The genetic de-
fects in these patients (who sometimes have additional readily
recognizable features) make them unable to effectively cope
with the challenging pathogen, thus giving the picture of FHL.15
Cases with no evidence of familial recurrence have been called
‘‘secondary,’’ but we prefer to call them ‘‘sporadic.’’ For instance,
HLH can develop as a complication of juvenile idiopathic arthritis
(these cases have been called macrophage activation syndrome
[MAS]) or during immunosuppressive therapies for cancer or
autoimmune disorders,4,16 although it can occur also in the course
of protozoal (leishmaniasis and malaria), rickettsial,17 or myco-
bacterial infection. In a proportion of cases of sporadic HLH,
one finds cytocidal defects similar (although less profound) to
those seen in patients with FHL. In the remaining cases of spo-
radic HLH, tests currently in use do not detect functional abnor-
malities, although we suspect that they exist.
The natural course of HLH is life-threatening (almost invari-
ably so in patients with FHL) unless appropriate therapy is
promptly instituted.3 Two trials of the Histiocyte Society have es-
tablished the combination of etoposide and dexamethasone as the
standard of care.18,19 This treatment is aimed to bridging the time
gap until it is practical to carry out an allogeneic hematopoietic
stem cell transplantation (HSCT), which, by replacing genetically
defective bone marrow–derived cells with normal cells, provides
cure for most patients.20-22 Patients with sporadic disease have a
similar clinical picture, and they respond to the etoposide/dexa-
methasone protocol as in patients with FHL. However, unlike pa-
tients with FHL, once in remission, they remain disease free,
without any further therapy.3,4,18,19 Thus patients with HLH are
a dual diagnostic challenge. First, the clinical suspicion of HLH
ought to be confirmed quickly, so that treatment can be started
promptly to prevent organ damage and the risk of a fatal outcome.
Second, it is important to distinguish FHL from sporadic HLH, so
that HSCT can be organized speedily for patients with FHL and,
just as importantly, patients with sporadic HLH are spared unnec-
essary HSCT.
Over the past 25 years, we have collected data on patients in
whom a clinical diagnosis of HLH has beenmade by the attending
clinicians. Here we report on those 500 patients in whom the
diagnosis of HLH was subsequently confirmed.METHODS
Starting from 1989, we centralized patient information and biologic samples
to support the provisional clinical diagnosis of HLH and to perform
immunologic and genetic studies of Italian patients, who were defined as such
if living in Italy.3 All centers of the national pediatric hematology-oncologycooperative group (Associazione Italiana Ematologia Oncologia Pediatrica)
agreed to refer their patients’ samples and information. Furthermore, in some
cases samples of adult patients with a similar clinical picture are also referred.
HLH was defined according to the diagnostic criteria recommended by the
Histiocyte Society (see Table E1 in this article’s Online Repository at www.
jacionline.org).23 In 98 patients preliminarily reported as having HLH, the
diagnosis was modified (acute infection, n 5 19; cancer [lymphoma, n 5 5;
leukemia or myelodysplastic syndrome, n 5 8; or brain tumor, n 5 2],
n 5 15; liver failure, n 5 12; encephalopathy, n 5 12; autoimmune lympho-
proliferative syndrome, n 5 8; cytopenia, n 5 8; other congenital disorder,
n 5 7; lysinuric protein intolerance, n 5 5; primary immune deficiency,
n 5 4; congenital storage disease, n 5 4; and Langerhans cell histiocytosis,
inflammatory bowel disease, healthy subject, and other undefined, n 5 1
each). Therefore these patients were excluded from this analysis.
Data on the family history and clinical and laboratory presenting features
are collected on a specific form and stored in a dedicated Microsoft Access
database. A unique patient number encodes the patients.
Peripheral blood samples from the patients are shipped overnight. Patients
are tested before treatment start or during steroidmonotherapy, which does not
modify the results.24 We perform immunologic screening assays,25-30 and in
case of abnormalities compatible with the clinical suspect, mutation analysis
is started. In some patients receiving a diagnosis before immunologic assays
were available or material from whom was inadequate for functional assays,
mutation analysis was directly performed. The strategy of mutation analysis
is as follows: in patients with defective perforin expression, PRF1 is
sequenced; in patients with a degranulation defect, UNC13D, STX11, and
STXBP2 are sequenced in that order; in patients with pigment deficiency,
RAB27a and then LYST are sequenced; in male patients with defective SAP
expression and/or inhibitory instead of activating 2B4 receptor function,
SH2D1A is sequenced; and in male patients XIAP staining is also performed,
and XIAP is sequenced. Archive cases with suspected but undefined genetic
disease were progressively retrieved and analyzed when additional genes
became available for testing.
Immunologic analyses and mutation analysis
Measurement of protein expression, granule release assays, cytotoxicity
assays, and mutation analysis were performed, as previously described.25-30
Details are available in the Methods section in this article’s Online Repository
at www.jacionline.org.
Statistical analysis
Statistical significance of the differences between the presence or absence
of biallelic mutation for each age group has been evaluated by using the x2 test
(GraphPad Prism 6; GraphPad Software, La Jolla, Calif). Differences have
been considered significant at a P value of less than .05.
Ethics statement
The attending physician obtained written informed consent for data
collection, immunologic studies, and genetic studies for all patients and
familymembers. The studywas approved by the Institutional ReviewBoard of
the A.O.U. Meyer, Florence, Italy. All clinical investigations were conducted
according to the principles expressed in the Declaration of Helsinki.RESULTS
Study population
The mean annual accrual to the Italian Registry increased
steadily over the study period (see Table E2 in this article’s Online
Repository at www.jacionline.org), with a total of 500 patients
enrolled. There were 259 male and 241 female patients. Age at
the time of diagnosis ranged from 0 to 60 years (Fig 1), with a me-
dian of 2.2 years. Although the vast majority of patients were chil-
dren, 44 (8.8%) were older than 18 years at the time of diagnosis.
FIG 1. Distribution of patients with FHL (biallelic mutations; gray bars) or sporadic HLH (no biallelic muta-
tions; white bars), according to age at diagnosis. The number of patients for each age group is indicated
within each bar. *P < .001, x2 test.
FIG 2. Diagnosis and classification of HLH. Distribution of 500 patients with
HLH according to the presence or absence of biallelic mutations in any of
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433 (87%); eastern European, 14; African, 12; Asian, 13; Hispanic,
6; other/not known, 22. Parental consanguinity was reported in 40
(8%) and familial recurrence of the disease in 75 (15%) patients.
Immunologic studies
In 33 (6.6%) cases the blood sample received was insufficient
or inadequate for any diagnostic study. In a further 95 cases
insufficient cell viability prevented us from performing functional
assays. In the remaining 372 (74%) cases we performed at least 1
immunologic test (Fig 2 and Table I). Absent perforin expression
was always predictive of biallelic PRF1 mutations. A complete
degranulation defect was also predictive for biallelic mutations
in one degranulation-related gene (UNC13D, STXBP2,
RAB27A, or LYST). Seven of 8 patients with FHL with normal
perforin and degranulation assay results fell within the XLP cate-
gory, confirming that the degranulation assay is not the test of
choice for these patients.the FHL-related genes is shown. Not all patients were investigated for the 3
functional assays. In 275 patients functional testing was followed by
mutation analysis. Patients were classified as having sporadic HLH if they
had no evidence of a severe functional defect and did not have biallelic
mutations in any FHL-related genes. Patients were classified as having
genetic HLH (or FHL) if they had biallelic mutations, with the only exception
of 15 patients given a diagnosis of FHL for clinical reasons in whom
mutations were not found. A possible simple explanation is that the
underlying gene or genes have yet to be discovered. Their details are
summarized in Table E3.Mutation analysis
DNA studies were carried out in 426 (85%) patients, of whom
(1) 275 had abnormal results on at least 1 immunologic assay; (2)
95 could not have immunologic screening performed; and (3) 56,
despite normal immunologic test results, were suspected of
having FHL based on 1 of the following: consanguinity, familial
TABLE I. Correlation of perforin expression and degranulation
assays in 372 patients with HLH in whom at least 1 of the
immunologic assays could be performed
Perforin
expression
Degranulation
TotalNormal Reduced
Complete
defect Not performed
Normal 106 (8) 34 (8) 29 (29) 46 (13) 215 (58)
Reduced 26 (5) 10 (1) 3 (3) 33 (8) 72 (17)
Absent 12 (12) 1 (1) 0 17 (17) 30 (30)
Not performed 11 (2) 2 (0) 1 (1) 41* (25) 55 (28)
Total 155 (27) 47 (10) 33 (33) 137 (63) 372 (133)
The number of patients with biallelic mutations defining the diagnosis of FHL are
shown in parentheses. All of the patients with absent perforin expression or complete
degranulation defects (shown in boldface) had biallelic mutations in PRF1 or one
degranulation-related gene, respectively.
*In these 41 patients (32 of whom received a diagnosis within the year 2000 and none
during the last 5 years), the only immunologic test performed was the cytotoxicity
assay, results of which were normal in 5, reduced in 10, severely depleted in 26
patients.
FIG 3. Breakdown of the different genetic subtypes in 171 patients with FHL
or FHL-related disease. For each subtype, the name of the gene, the
abbreviation of the disease subtype, the absolute number, and the per-
centage are shown. Furthermore, we include as FHL one subgroup of 15
patients with either familial recurrence and/or refractory/recurrent disease
despite specific therapy and/or repeatedly documented severe functional
defect in degranulation or cytotoxicity assays (see Table E3).
TABLE II. Different mutations identified in patients with FHL
PRF UNC13D STXBP2 STX11 RAB27A
Missense 20 11 4 0 1
Nonsense 6 8 0 0 1
Deletions/insertions 8 12 3 1 3
Splicing 0 6* 0 0 0
Total 34 37 7 1 5
*Transcript defects were all documented at the RNA level.
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disease reactivation.Patients with FHL
Mutation analysis revealed biallelic pathogenic mutations in
171 (40%) patients. According to the genes in which we found
mutations, these were further subclassified into genetic subtypes
(Fig 3).
In the 69 patients with FHL2, we identified 34 different PRF1
mutations (Table II); 28 patients were homozygous for theirPRF1
mutation. The most frequent mutations were c.1122G>A
(p.W374X), which is present in 19 patients; c.272C>T
(p.A91V), which is present in 11 patients; c.657C>A
(p.Y219X), which is present in 10 patients; and c.695G>A
(p.R232H), which is present in 9 patients. Themedian age at diag-
nosis was 0.2 years (0.18 years for homozygotes and 0.29 years
for biallelic heterozygotes), and the range was 0 to 49 years.
In the 62 patients with FHL3, we found 37 different UNC13D
mutations (Table II). The most frequent mutations werec.75311G>T (splice error), which was present in 19 patients;
c.2346_2349delGGAG (p.R782Sfs), which was present in 11 pa-
tients; and c.1847A>G (p.E616G), which was present in 8 pa-
tients. Twenty-two patients were homozygotes, and 32 had at
least 1 splice defect mutation. Just like in the FHL2 group, theme-
dian age at diagnosis was earlier in homozygotes (0.32 years) than
in heterozygotes (1.5 years).
In 26 families we had 2 sibs in our registry. In 16 cases the age
at which the disease manifested was very close in the 2 affected
sibs. However, in 9 cases we observed an age difference of
between 46 and 207 months, and in 1 case one sib had the disease
at 6.7 years, whereas the other remains unaffected at the age of
25 years (Fig 4).
In 15 patients (3.5% of the patients in whom we performed
mutation analysis and 3% of the total patients enrolled, see Table
E3 in this article’s Online Repository at www.jacionline.org), we
found no pathogenic mutations in FHL-related genes in spite of
the fact that we had strongly suspected FHL on the grounds of fa-
milial recurrence (n 5 6), confirmed severe immunologic defect
(n 5 3), immunologic defect associated with pigment deficiency
(n5 1), or recurrent and fatal disease (n5 5). These last 5 patients
were given diagnoses when 24 months old or less, between 1983
and 1996; of them, 1 patient had absent NK cell activity, and mu-
tation analysis could not be completed in any of thembecause lack
ofmaterial; if this had been done, we hypothesized that theymight
have likely been classified in one of the known FHL subtypes.
Patients with sporadic HLH
Two hundred eighty-one patients (56% of the total) were
categorized as having sporadic HLH on the following grounds.
First, in 41 patients immunologic test results were normal. In
these patients mutation analysis was not carried out. Second, in
197 patients we found no mutations in FHL-related genes. Third,
43 patients had monoallelic mutations in 1 (n 5 41) or 2 (n 5 2)
FHL-related genes (PRF1, n 5 25; UNC13D, n 5 10; STX11,
n 5 2; STXBP2, n 5 6; and RAB27A, n 5 2; Fig 2).
None of the patientswith sporadicHLHhad a complete defect of
either perforin expression or degranulation. To establish correla-
tions between the outcome of immunologic assays andmonoallelic
mutations in patients with sporadic HLH, we found that of 55
patients with reduced (but not absent) perforin expression, 47 were
sequenced, and 15 (32%) had monoallelic PRF1 mutation. Of 37
patients with reduced (but not absent) degranulation, 35 were
sequenced, and 8 (23%) had monoallelic mutation in UNC13D
(n 5 4), STXBP2 (n 5 3), or RAB27A (n 5 1).Survival
Overall, at the time of writing, 159 (31.8%) of the 500 patients
had died. In the various subgroups the mortality rates were as
follows: 50.8% of the 171 patients with FHL with biallelic
FIG 4. Intrafamilial variation of age at onset of FHL in 26 families with more than 1 affected case. In families
23 and 26, 3 affected cases are reported. In families 4, 9, and 18, the siblings were concordant twins. *This
sibling of patient 24 is now 25 years old and has not yet had the disease. The FHL genetic subtype is
indicated at the bottom, with the exception of family 25 (FHL5) and family 26 (Griscelli syndrome type 2).
The type of mutations are abbreviated as follows: C, combination of 1 nonsense and 1 missense mutation;
M, biallelic missense mutations; N, biallelic nonsense mutations. **Case 25, FHL5; case 26, Griscelli syn-
drome type 2.
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mutations; and 41.6% of the 72 patients not analyzed for
mutations.
Among the 281 sporadic cases, 11% died (including 2 after
HSCT) at a median of 29 days from diagnosis; there was no
significant difference in mortality between patients with mono-
allelic mutations (5/43 [12%]) and those with no mutations (26/
197 [13%]; P 5 .84, x2 test; odds ratio, 0.91).DISCUSSION
In this article we summarize the experience accumulated over
25 years through the study of 500 unselected patients with HLH
resident in Italy. Among 50 units that normally refer patients to
our registry, 14 pediatric hematology-oncology units have
referred more than 10 cases each (range, 11-48 cases). The steady
increase in patient accrual over the study period must mean that
there is increased awareness of HLH among pediatricians and
other doctors. Overall, about one third of the patients had biallelic
mutations (ie, they had FHL by definition). Thus the frequency of
patients with FHL in Italy is comparable with that reported in
Nordic countries (around 1:50,000 children).31 Interestingly, over
the years, the ratio between FHL cases and sporadic HLH cases
has gradually decreased by more than 3-fold (see Table E2), indi-
cating increased recognition not just of FHL but also of HLH in
general.
The median age at diagnosis was 2.2 years. Nearly two thirds
(94/147 [64%]) of patients given a diagnosis before the age of
1 year had FHL; this proportion decreased to 27% in the second
year and remained roughly the same at higher ages (Fig 1),including in adults. This still relatively high proportion of FHL
in adults has major implications for adult hematology.32-34
Another surprising finding was that when more than 1 sib was
affected within the same sibship, in two thirds of cases, there
was a wide gap between the age at diagnosis of the 2 (or 3)
sibs. In an extreme case a child had the disease at 6.7 years,
whereas his sister, who also has biallelic mutations, has not yet
had HLH by the age of 25 years. As a kind of internal control,
in one third of cases, the age at which 2 sibs had HLH was very
similar (Fig 4).
Increasing immigration from countries with limited resources
brings new citizens into Italy. Among 55 such patients, 18
harbored biallelic mutations, and their subtype distribution
appears no different from that of the autochthonous patients.
Our registry also containsmore than 500 additional cases who live
in other countries: we have not included them in our analysis
because in these referrals from abroad, there might have been
considerable selection bias.Identifying FHL
A priority of a reference laboratory must be to differentiate
FHL from sporadic HLH in as many cases as possible as promptly
as possible. One major finding of our study is that we did not find
biallelic mutations in only 8% of patients (3.5% of the total)
presumed to have FHL. The most likely explanation is that this
small minority of patients with FHL might have mutations in 1 or
more gene(s) that have not yet been identified as FHL related. At
any rate, in the large majority of cases, we are able to classify
correctly patients as having FLH versus sporadic HLH. This has
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with respect to the selection of a family donor, genetic counseling,
and prenatal diagnosis. Health services have invested significant
resources for the definitive diagnosis of these patients and
provided information that will be most helpful to future patients
in return. In addition, they have contributed in a uniqueway to our
understanding of the killing mechanism through granule exocy-
tosis and perforin, as well as shedding light on unexpected
interactions among the various proteins involved.35-37
The breakdown of gene-specific subtypes of FHL confirms that
in southern Europe FHL2 and FHL3 together account for 70% of
the cases. In patients with FHL2, the W374X mutation has been
previously reported as being associated with Turkish origin.38
This is not surprising given the migratory exchanges that have
occurred over 2 millennia between the Italian and Turkish popu-
lations, and it suggests that this mutation has an ancestral origin.
Three patients were homozygous for A91V, a mutation present in
about 5% of the European population39-41; for this reason, its
pathogenic role has been questioned. On the other hand, it has
been documented that this amino acid replacement is detrimental
to the perforin protein.30,39,42 HLH developed in 2 of our 2 homo-
zygous patients before the child was 1 year old. The condition
presented with severe liver dysfunction, perforin expression was
either absent or markedly reduced (data not shown), and no mu-
tations were found in any of the other FHL-related genes. The
third patient had a full-blown HLH picture at the age of 49 years
after having been given a previous diagnosis of rheumatoid
arthritis. Thus we consider A91V to be pathogenic. Its high prev-
alence might suggest an as yet unidentified selective advantage,
which deserves investigation. We observed one cluster of FHL2
in Campania and another in Sicily, but the mutations found
were different.
In 50% of patients with FHL3, we found at least 1 splice defect
of UNC13D, thus confirming the initial report by Santoro
et al.43-46 Only 1 patient (not autochthonous Italian) had the
c.118-308C>T intronic mutation.47 None of the patients carried
the 253-kb inversion, which is observed in North America48;
the c.159611G>C mutation, which is common in Japan49; or
the c.754-1G>C mutation, which is present in the majority of pa-
tients with FHL3 in Korea.50
All the remaining genetic subtypes are represented in our
geographic area, with 10% for XLP, 5% for FHL5, and a single
autochthonous family with FHL4.Sporadic cases
We have adopted the term sporadic in analogy to current use
with respect to other diseases for those 56% of patients who have
no family history and no evidence of a severe immunologic defect
(based on a panel of tests) and in whom we did not find biallelic
mutations on mutation analysis. As for clinical presentation,
sporadic HLH is a phenocopy of FHL.3,4,19 Although in sporadic
cases the overall prognosis is much better than in patients with
FHL, in our series 31 (11%) of them died (including 2 patients
who had received HSCT) from either the disease or from
treatment-related complications at amedian of 29 days from diag-
nosis. This finding is in keeping with the report from the HLH-94
trial, in which the lack of familial disease (defined only on the ba-
sis of familial recurrence) was not associated with a significantly
better outcome.19 This implies also that sporadic HLH treatment
must be prompt and must be continued until disease control hasbeen achieved, with the reasonable expectation that reactivation
is unlikely.3,4,18,19
Interestingly, 43 (18%) of the 240 patients with sporadic HLH
had monoallelic mutations in one FHL-related gene, thus
providing a tangible link between FHL and sporadic HLH. Of
course, we must be cautious in interpreting this finding, which
could have several explanations. First, in some patients we might
have simply missed a second mutation (the finding of mutations
deep in the introns ofUNC13D has taught us a lesson45), in which
case they would have true FHL. Second, some of these monoal-
lelic mutations are polymorphic in the general population (eg,
PRF1-A91V, which has been already mentioned, as well as
some others). Therefore they might or might not be relevant to
pathogenesis. Even if we take these 2 possibilities into account,
we believe that the association with HLH of monoallelic muta-
tions at FHL-related loci cannot be just coincidental because their
frequency is much higher than could ever be observed in healthy
control subjects. In addition, it stands to reason that a monoallelic
loss-of-function mutation could cause an impairment in the
granule exocytosis pathway or perforin expression. Indeed, on
testing 28 of the 43 patients with a monoallelic mutation, we
observed that none of them had a complete defect but 11 had a
partial degranulation defect (17 had normal results).
Thus, as a group, patients with HLH are highly enriched for
monoallelic mutations in those same genes that produce FHL
when both alleles are mutated. In other words there is a gene
dosage effect whereby FHL can no longer be regarded as a
straightforward recessive disease. This can be explained in
mechanistic terms by considering that patients with monoallelic
mutations are haploinsufficient for genes involved in their
perforin-dependent killing function. As yet, we are unable to
provide a quantitative estimate for the risk of HLH in any person
with a monoallelic mutation in one of the FHL-related genes: it is
certainly less than in persons who have biallelic mutations but
probably much higher than in the general population. From the
practical point of view, sporadic HLH flips to FHL when another
child in the same family had the disease and a member of the
medical team recognizes this, which is exactly what happened in
the families listed in Fig 4.
If patients withmonoallelic mutations are, in away, themissing
link between FHL and sporadic HLH, perhapswe canvisualize all
patients with HLH as being part of a spectrum (Fig 5).We surmise
that, depending on the genotype of the patient, more or less
powerful triggers are required before the clinical picture of
HLH explodes. In addition to the relatively frequent finding of
monoallelic mutations in patients with sporadic HLH, several
lines of evidence support this notion.
First, it is a given that there is always a trigger for the disease,
even in those with FHL, in whom the trigger is thought to be
mostly a viral infection that genetically defective cytotoxic T
lymphocytes are unable to clear.
Second, although patients with FHL are prone to disease
recurrence, a trigger is again required.
Third, without a trigger, the disease can be offset for years
(Fig 4). Of course, because we are comparing sibs (not identical
twins), modifier genes might also play a role here.
Fourth, in the HLH-94 trial patients who did not have familial
disease more frequently had a recent infection.19
Finally, at the other end of the spectrum, hemophagocytic
syndrome is awell-known if rare complication of severe bacterial,
rickettsial, or protozoal infections.17 That in such cases the
FIG 5. The risk of HLH results from the interaction of a predisposed
genotype and environmental triggering factor or factors. Genotype is
intended as in the FHL-related genes (PRF1, UNC13D, STX11, STXBP2,
RAB27A, LYST, SH2D1A, XIAP, and AP3B1). Patients with sporadic HLH
and no mutation found might harbor mutation(s) in other gene(s) currently
not identified as FHL related. Selected patients might have HLH, classified
as sporadic, as the presenting clinical manifestation of juvenile idiopathic
systemic arthritis (MAS). Common viral pathogens can behave as a trigger
for both HLH or FHL; among them, EBV or other herpesviruses are the most
frequently reported.
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bial therapy (and no other therapy) is good evidence that infection
is indeed the trigger. Interestingly, we had 11 patients with HLH
secondary to visceral leishmaniasis, and none of them had a
monoallelic mutation (data not shown).
A related finding was reported recently by the Cincinnati
group. Through whole-exome sequencing of DNA from patients
with rheumatoid disorders who had MAS, they found variants in
FHL-related genes, as well as new candidate genes,51 andwe have
found that a proportion of patients with MAS harbor monoallelic
mutations in FHL-related genes (manuscript in preparation). We
can expect that the set of genes that predispose to HLH might
expand further, particularly genes involved in inflammation.52,53
In the meantime, it appears that patients with MAS also fit well
in the spectrum illustrated in Fig 5.Role of immunologic assays
A complete defect of perforin expression or degranulation
capacity was always associated with biallelic mutations in the
respective genes,24-26 and these 2 defects were mutually exclusive
(Table I). In approximately one quarter of cases of sporadic HLH,
partial reduction of either perforin expression or degranulation
heralded monoallelic mutation in one corresponding gene, con-
firming a dosage effect.24 Another interesting question that de-
serves investigation is which nongenetic mechanisms might
cause (down)regulation of these properties in the remaining cases
presenting with a partial functional defect. Serial monitoring of
sporadic cases found at diagnosis to have partial expression of
perforin or impairment of degranulation is warranted and is
now ongoing. At any rate, although in our hands these functional
studies have proved useful to triage samples on which mutation
analysis is imperative (Fig 2), we recognize that with the increase
in massive sequencing, very soon mutation analysis might
become the primary diagnostic approach for discriminatingFHL from sporadic HLH. As a result, sophisticated assays, such
as cytotoxicity and degranulation, informative on function but
laborious and requiring specific expertise, might be progressively
abandoned.
Diagnostic criteria might need to be updated
In our series nomore than 40% of patients (data not shown) had
hemophagocytosis at diagnosis. Therefore even though hemo-
phagocytosis is a time-honored pathologic feature of HLH and is
diagnostically useful when present, wemust recommend that it be
dropped as a diagnostic criterion. The cytotoxicity assay was used
in this series in 44% of patients but in only 18% during the last
5 years; in practice it can be replaced by protein expression/
degranulation assays.24-29 It would be desirable to compare a
group of patients such as this one with matched non-HLH group
of patients who have septicemia or inflammatory diseases to
achieve an unbiased assessment of old and new diagnostic tests.
The time might have come for a consensus conference that will
update recommendations regarding the most appropriate diag-
nostic tests.
In conclusion, while giving credit to Bodley-Scott and Robb-
Smith for their seminal work on HLH,1 we must state today that
the ultimate diagnosis of this disease is not through microscopy.
These authors could not have surmised that there is a strong ge-
netic component in at least a substantial proportion of cases,
and our data show clearly that the diagnosis must be based on a
combination of targeted molecular analysis and specific func-
tional studies of lymphocytes. We have shown that by detecting
biallelic mutations, we can promptly identify patients with FHL
and that children with HLH during the first year of life have a
strikingly high probability to have FHL, with FHL2 and FHL3 be-
ing the most frequent genetic subtypes in southern Europe. It is
gratifying that with earlier accurate diagnosis, the prognosis has
tangibly improved. In our systematic analysis of 500 cases of
HLH, we have foundmonoallelic mutations in FHL-related genes
in 15% of cases of sporadic HLH: this must mean that these mu-
tations can make the function of the other allele inadequate in the
face of certain challenges (haploinsufficiency). Whether we clas-
sify these cases as familial or sporadic becomes a matter of se-
mantics, but clearly, we can no longer simply say that FHL is
recessive. At the same time, one wonders whether patients with
sporadic HLH in whomwe find nomutation in FHL-related genes
might havemutations in other genes, such as those that control the
production or secretion of IFN-g. This question should be soon
settled by using full-exome sequencing.
In the meantime, it appears reasonable to surmise that the
explosion of HLH is like being pushed over the edge into a
potentially catastrophic drop. If the push (eg, an infectious
trigger) is powerful enough, anybody can be made to fall, but if
the edge is lowered (certain genes are mutated), a much weaker
push might be sufficient to produce the same result. This will be
true of persons with a monoallelic mutation and even more of
those with biallelic mutations.
We thank G. Griffiths (Cambridge) for her contribution in the character-
ization of selected patients, Luca Cavalli Sforza (Milano) for advising on
interpretation of data on Italian population genetics, and Benedetta Ciambotti,
Martina Da Ros, and Maria Luisa Coniglio (Florence HLH laboratory) for
their contribution to the diagnostic studies. The following 14 Italian centers
reported 10 or more patients to the HLH Registry (current chairperson of the
center): Ancona, Clinica Pediatrica, Centro Regionale Oncoematologia
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CETICA ET AL 195Pediatrica Ospedale dei Bambini G. Salesi (P. Pierani); Bari, Dipartimento
Biomedicina Eta Evolutiva U.O. Pediatrica I Policlinico (N. Santoro);
Bergamo, Ospedale Papa Giovanni XXIII U.O. Pediatria, Sezione Oncoema-
tologia Pediatrica (M. Provenzi); Bologna, Oncologia ed Ematologia
Pediatrica ‘‘Lalla Seragnoli’’ Clinica Pediatrica Policlinico Sant’Orsola
Malpighi (A. Pession); Brescia, Clinica Pediatrica oncoematologia pediatrica
e TMO Ospedale dei Bambini (F. Porta); Firenze, Dipartimento A.I.
Oncoematologia, SODC Tumori Pediatrici e Trapianto di cellule staminali,
A.O.U Meyer (C. Favre); Genova, Dipartimento di Ematologia e Oncologia
Pediatrica, Istituto G.Gaslini (F. Frassoni); Monza, Clinica Pediatrica Uni-
versita Milano–Bicocca, A.O. San Gerardo–Fondazione MBBM (A. Biondi);
Napoli, Dipartimento di Oncologia, A.O. Santobono-Pausilipon (V. Poggi);
Palermo, U.O Oncoematologia Pediatrica, ARNAS Civico Di Cristina e
Benfratelli (P. D’Angelo); Padova, Dipartimento di Pediatria, Universita di
Padova, Cattedra di Oncoematologia Pediatrica (G. Basso); Pavia, Oncoema-
tologia Pediatrica, Fondazione Irccs, Policlinico San Matteo (M. Zecca);
Roma, Oncoematologia Pediatrica, Ospedale Bambino Gesu (F. Locatelli);
and Torino, S.C. Oncoematologia Pediatria e Centro Trapianti, Ospedale
Infantile Regina Margherita (F. Fagioli).
Clinical implications: The analysis of 500 patients with HLH
enrolled in the last 25 years could help redefine the clinical pic-
ture of this condition and revise the diagnostic approach.REFERENCES
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METHODS
Diagnostic strategy in patients with HLH
Immunologic tools have been developed to pinpoint rapidly those patients
who have the most frequent defects underlying FHL to speed up the procedure
of discrimination between sporadic cases and cases with biallelic mutations.
Flow cytometric analysis of peripheral blood lymphocytes allows detection of
defective intracytoplasmic perforin expression and SAP and XIAP expression
and reduced capacity of the stimulated cytotoxic lymphocytes to ‘‘degranu-
late,’’ asmeasured by induced surface expression of the CD107amolecule.E1-E4
Additional tools have been developed to investigate SAP and XIAP expression
in male patients with suspected HLH-related conditions.E5,E6 Detection of
defective cellular cytotoxicity, although included in the diagnostic criteria,
requires the use of radionuclides, which makes it impractical; thus its use has
been progressively restricted to investigation of highly selected patients, mostly
for research purposes. Because the above methods require specific skills,
regional reference laboratories have been developed.E7
Immunologic analyses
Protein expression, degranulation, cytotoxicity assays, and mutation
analysis were performed, as previously described.E1,E2,E4-E7 PBMCs from pa-
tients and healthy donors were isolated by means of Ficoll gradient centrifu-
gation. NK cells were also purified by using the RosetteSepmethod (StemCell
Technologies, Vancouver, British Columbia, Canada), according to the man-
ufacturer’s instructions. NK cells were cultured on irradiated feeder cells in
the presence of 2 mg/mL PHA (Sigma-Aldrich, Irvine, United Kingdom)
and 600 IU/mL rIL-2 (Proleukin; Chiron, Emeryville, Calif) to obtain high
numbers of polyclonal activated NK cell populations.
Perforin expression on NK cells (CD32CD561 cells of peripheral blood
lymphocyte or purified activated NK populations) was detected by means of
intracellular staining (after fixation and permeabilization) with dG9 mAb
(IgG2b) and cytofluorimetric analysis, as previously reported.
E2 Intracellular
SAP expression with the 1C9 mAb (IgG2a; Abnova, Taipei, TW) and staining
with anti-XIAP (IgG1; BD Bioscience, San Jose, Calif) were evaluated, fol-
lowed by phycoerythrin-conjugated isotype specific second reagents (South-
ernBiotech, Birmingham, Ala). Mouse isotype-matched control mAbs (BD
Bioscience) were used.E5,E6
To analyze the cytolytic activity in 4-hour 51Cr-release assays, PBMCs
were tested against K562 cells and activated NK cells were tested against
the HLA class I2 B-EBV cell line 721.221, which were demonstrated to be
suitable effector/target combinations to reveal cytolytic defect of patients
with FHL. Effector cell/target cell ratios ranging from 100:1 to 1:1 were
used for PBMCs as effector cells, whereas ratios ranging from 8:1 to 0.5:1
were used for activated NK cells. Lytic units at 30% lysis were calculated.
Resting and activated NK cells were also tested in degranulation assays quan-
tifying cell-surface CD107a expression on coculture with K562 cells, as pre-
viously described.E3 Briefly, anti-CD107a–phycoerythrin mAb was added
during the coculture for 3 hours at 378C in a 5% CO2 atmosphere. Thereafter,
the cells were stained with anti-CD56–allophycocyanin and anti-CD3–peridi-
nin-chlorophyll-protein complex mAbs and analyzed by using flow cytometry
(FACSCalibur, Becton Dickinson). All reagents were from BD Biosciences.
Surface expression of CD107awas assessed in the CD32CD561 cells. Results
were evaluated as DCD107a (ie, Percentage CD107a1 cells of stimulated
samples2 Percentage of CD107a1 cells of unstimulated samples) and defined
as defective when lower than the tenth percentile of healthy control subjects.
2B4 function was evaluated in degranulation or 51Cr release assays by using
either PBMCs short-term culturedwith rIL-2 or activatedNK cells as effectors
in reverse antibody-dependent cellular cytotoxicity against the P815
(FcgRc1) target cell line in the presence of functional grade purified
anti-2B4 mAb (PP35; eBioscience, San Diego, Calif) alone or in combination
with the anti-NKp46 mAb (9E2; Miltenyi Biotec, Bergisch Gladbach, Ger-
many; or BAB281 cells).E5,E6
Mutation analysis
Genomic DNA was isolated from peripheral blood samples by using the
BioRobot EZ1 Workstation (Qiagen, Jesi, Italy) or QIAamp DNA Mini Kit
(Qiagen). PRF1 (OMIM *170280),UNC13D (*608897), STXBP2 (*601717),
and STX11 (*605014) have been analyzed in all patients. Male patients were
also tested for SH2D1A (*300490) and XIAP (*300079). Where pigment defi-
ciency was reported, samples underwent RAB27A (*603868) or LYST
(*606897) gene analysis. Briefly, coding exons and exon-intron boundaries
of the FHL-related genes were amplified and directly sequenced in both direc-
tions with the BigDye Terminator Cycle SequencingReady Reaction Kit
(Applied Biosystems, Foster City, Calif). Amplification reactions were per-
formed with 60 ng of DNA, 10 ng of each primer, 200 mmol/L dNTPs, 13
PCR reaction buffer, and 2.5 U of Taq polymerase in a final volume of
25 mL. Sequences obtained with an ABI Prism 3130XL Sequence Detection
System (Applied Biosystems) were analyzed and compared with the reported
gene structure by using the dedicated software SeqScape (Applied Bio-
systems). All mutations were confirmed in the parents and tested in all avail-
able family members on request.
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TABLE E1. Revised diagnostic guidelines for HLHE7
The diagnosis of HLH can be established if either 1 or 2 of the following are
fulfilled:
1. A molecular diagnosis consistent with HLH (ie, biallelic mutations in 1
FHL-related gene)
2. Clinical and laboratory criteria for HLH fulfilled (>_5 of the following 8
criteria fulfilled):
Fever
Splenomegaly
Cytopenia (affecting >_2 of 3 lineages in peripheral blood):
Hemoglobin <9 g/dl (in infants <4 wk: Hb <10 g/dL)
Platelets <100 3 109/L
Neutrophils <1.0 3 109/L
Hypertriglyceridemia and/or hypofibrinogenemia
Fasting triglycerides >_3.0 mmol/L
Fibrinogen <_1.5 g/L
Hemophagocytosis in bone marrow or spleen or lymph nodes
Low or absent NK cell activity
Ferritin >_500 mg/L
Soluble CD25 (ie, soluble IL-2 receptor) >_2400 U/mL
Additional features, such as:
d Cerebral symptoms with moderate pleocytosis and/or increased protein
levels in cerebrospinal fluid
d Increased transaminase levels
d Increased bilirubin levels
d Increased lactate dehydrogenase levels
Might be present in a minority of cases and thus their presence might
contribute to suspicion of HLH.
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TABLE E2. Number of cases of HLH reported to the Italian National registry by time interval
Time interval
Total no. of patients
(mean no. per year)
Patients with
biallelic mutation
(mean no. per year)
Sporadic patients
(mean no. per year) Biallelic/sporadic ratio
1989-1994* 53 (8.8) 28 (4.6) 25 (4.1) 1.12
1995-1999 46 (9.2) 28 (5.6) 18 (3.6) 1.55
2004-2004 67 (13.4) 32 (6.4) 35 (7.0) 0.91
2005-2009 127 (25.4) 37 (7.5) 90 (18.0) 0.41
2010-2014 207 (48.7) 48 (11.2) 159 (37.4) 0.30
Total 500 173 327 0.52
Note: The frequency is corrected according to the observation times as follows: *6 years for the initial cohort; 4.3 years for the most recent cohort ending March 31, 2014. The
current total number of inhabitants in the country is 59,685,227, including 521,855 newborns in 2013 (http://demo.istat.it/pop2013/index.html).
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TABLE E3. Main features of 15 patients given a diagnosis of FHL based on clinical or immunologic findings in which mutations
were not identified in any of the FHL-related genes
Unique
patient no. Origin Consanguinity
Familial
disease Sex/age Clinical course Functional studies
86* Italy Yes Yes M/1.4 Dead of progressive disease Not performed
176 Italy No Yes M/0.4 Dead of progressive disease Absent NK activity
186* Italy Yes Yes M/0.8 Dead of surgical complication, before
transplantation
Normal NK activity
331 Italy No No F/1.1 Recurrent disease, severe encephalopathy Normal perforin expression, GRA, and NK
activity
347 Italy No No F/2.1 Cured after transplantation Normal perforin expression, reduced GRA,
defective NK activity
456 Italy No Yes M/3.1 Dead of progressive disease Not performed
524 Italy No Yes F/3.4 Cured after transplantation Normal perforin expression, reduced GRA,
absent NK activity
540 Italy No No F/11.7 Dead of progressive disease Normal perforin expression, reduced GRA,
normal NK activity
587 Pakistan Yes Yes M/0.7 Dead of progressive disease Normal perforin expression, normal GRA
608 Italy No No F/3.8 Dead of progressive disease Normal perforin expression, GRA, and NK
activity
690 Italy No No M/0.2 Recurrent disease, severe encephalopathy Normal perforin expression and GRA
696 Italy No No M/0.7 Recurrent disease; dead of complication after
transplantation
Normal perforin expression and GRA; NK
activity mildly reduced
728 Asia No No F/2.4 Dead of progressive disease Normal perforin expression and GRA; NK
activity reduced
756 Italy No No M/2.4 Dead of progressive disease Not Performed
797 Italy No No M/1.7 Dead of progressive disease Normal perforin expression and GRA
F, Female; GRA, granule release assay; M, male.
*Unique patient numbers 86 and 186 are siblings.
Unique patient numbers 456 and 524 are siblings.
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